

PEAQX

Catalog No: tcsc3382



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

459836-30-7

Formula:

$C_{17}H_{17}BrN_3O_5P$

Pathway:

Membrane Transporter/Ion Channel;Neuronal Signaling

Target:

iGluR;iGluR

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

NVP-AAM077

Observed Molecular Weight:

454.21

Product Description


PEAQX(NVP-AAM 077) is a potent and orally active NMDA antagonist with a 15-fold preference for human NMDA receptors with the 1A/2A(IC₅₀=270 nM), rather than 1A/2B(29,600 nM).

IC₅₀ value: 270 nM(hNMDA A1/A2) [1]

Target: NR2A antagonist

in vitro: PEAQX has a high binding affinity for NMDA receptors (IC₅₀=8 nM), and a functional preference in excess of 100-fold for hNMDA 1A/2A (IC₅₀=of 270 nM) over 1A/2B receptors (IC₅₀=29,600 nM) [1].

in vivo: PEAQX is practically inactive in Xenopus oocytes expressing hNMDA 1A/2B receptors, displays an ED₅₀ value of 23 mg/kg in the MES test [1]. Sprague-Dawley rats were treated on PN7, PN9, and PN11 with PCP (10 mg/kg), PEAQX (NR2A-preferring antagonist; 10, 20, or 40 mg/kg), or ifenprodil (selective NR2B antagonist; 1, 5, or 10 mg/kg) and sacrificed for measurement of caspase-3 activity (an index of apoptosis) or allowed to age and tested for locomotor sensitization to PCP challenge on PN28-PN35. PCP or PEAQX on PN7, PN9, and PN11 markedly elevated caspase-3 activity in the cortex; ifenprodil showed no effect. Striatal apoptosis was evident only after subchronic treatment with a high dose of PEAQX (20 mg/kg). Animals treated with PCP or PEAQX on PN7, PN9, and PN11 showed a sensitized locomotor response to PCP challenge on PN28-PN35 [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!